Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 39CNS 38Thoracic 29Genitourinary 28Sarcoma 24Breast 22Head & Neck 21Lymphoid 19Other hematologic neoplasm 14Gynecologic 13Dermatologic 9Myeloid 4Other solid neoplasm 3Other 2Tumor-Agnostic 1Plasma cell 1NET 1Endocrine 1Classical hematology 1

Conditions

Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Radiation × Tumor-Agnostic × Clear all
NCT01706939 2026-04-09

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Icahn School of Medicine at Mount Sinai

Phase 3 Active not recruiting
23 enrolled 19 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡